115195
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
用于多囊卵巢综合征治疗的外泌体：机制和治疗潜力
Authors Liu P, Sha Y, Yang H, Liu T
Received 14 October 2025
Accepted for publication 1 January 2026
Published 10 January 2026 Volume 2026:21 574044
DOI https://doi.org/10.2147/IJN.S574044
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Sachin Mali
Pengyu Liu,1 Yanxiu Sha,2 Hailing Yang,3 Te Liu1
1Scientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People’s Republic of China; 2Department of Ophthalmology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People’s Republic of China; 3Department of Emergency, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People’s Republic of China
Correspondence: Hailing Yang, Department of Emergency, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People’s Republic of China, Email hlyang@jlu.edu.cn Te Liu, Scientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People’s Republic of China, Email iamliute@jlu.edu.cn
Abstract: Polycystic ovary syndrome (PCOS) is a major health concern for women of reproductive age and a leading cause of infertility and metabolic dysfunction. Current treatments mainly involve lifestyle modification and pharmacological therapies, such as oral contraceptives and metformin, and may also include laparoscopic ovarian drilling (LOD), acupuncture, and probiotic interventions. Although these approaches can be effective, they often produce adverse effects and show a high relapse rate after discontinuation. This review summarizes recent advances in exosome-based therapies as emerging strategies for PCOS. Exosomes derived from adipose-derived mesenchymal stem cells, menstrual blood–derived stem cells, bone marrow mesenchymal stem cells, brown adipocytes, and human umbilical cord–derived mesenchymal stem cells have demonstrated therapeutic potential. As nanosized extracellular vesicles carrying bioactive molecules, exosomes exhibit strong targeting capacity and low immunogenicity. We discuss the mechanisms by which exosomes may ameliorate PCOS, including suppression of chronic low-grade inflammation, enhancement of mitochondrial function, inhibition of apoptosis, modulation of angiogenesis, and improvement of metabolic disturbances. However, translating these promising findings into clinical practice faces significant challenges. The main obstacles include lack of standardization, high production costs, and limited clinical data to confirm safety and efficacy. Addressing these issues could pave the way for mechanism-based, personalized exosome treatments and offer new approaches for managing PCOS.
Keywords: polycystic ovary syndrome, exosome, personalized medicine
1Scientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People’s Republic of China; 2Department of Ophthalmology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People’s Republic of China; 3Department of Emergency, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People’s Republic of China
Correspondence: Hailing Yang, Department of Emergency, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People’s Republic of China, Email hlyang@jlu.edu.cn Te Liu, Scientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, People’s Republic of China, Email iamliute@jlu.edu.cn
Abstract: Polycystic ovary syndrome (PCOS) is a major health concern for women of reproductive age and a leading cause of infertility and metabolic dysfunction. Current treatments mainly involve lifestyle modification and pharmacological therapies, such as oral contraceptives and metformin, and may also include laparoscopic ovarian drilling (LOD), acupuncture, and probiotic interventions. Although these approaches can be effective, they often produce adverse effects and show a high relapse rate after discontinuation. This review summarizes recent advances in exosome-based therapies as emerging strategies for PCOS. Exosomes derived from adipose-derived mesenchymal stem cells, menstrual blood–derived stem cells, bone marrow mesenchymal stem cells, brown adipocytes, and human umbilical cord–derived mesenchymal stem cells have demonstrated therapeutic potential. As nanosized extracellular vesicles carrying bioactive molecules, exosomes exhibit strong targeting capacity and low immunogenicity. We discuss the mechanisms by which exosomes may ameliorate PCOS, including suppression of chronic low-grade inflammation, enhancement of mitochondrial function, inhibition of apoptosis, modulation of angiogenesis, and improvement of metabolic disturbances. However, translating these promising findings into clinical practice faces significant challenges. The main obstacles include lack of standardization, high production costs, and limited clinical data to confirm safety and efficacy. Addressing these issues could pave the way for mechanism-based, personalized exosome treatments and offer new approaches for managing PCOS.
Keywords: polycystic ovary syndrome, exosome, personalized medicine